ITD-1 is a novel selective TGF-β pathway-selective inhibitor that inhibits TGF-β activity by selectively degrading the TGF-β2 receptor at the proteosome level. ITD-1 does not block the closely related Activin A signaling pathway. ITD-1 stimulates embryonic stem cells to differentiate into cardiomyocytes (IC50 0.4-0.8 µM) by degrading the receptor and inhibiting intracellular signaling. ITD-1 has been formulated as a salt to increase stability and improve water solubility (~0.1 mg/mL) for ease of handling. As a salt, ITD-1 is chemically and metabolically stable and is non-cytotoxic. ITD-1 can be used to study a wide range of biological questions in cellular processing and TGF-β signaling.

ITD-1 is a novel selective TGF-β pathway-selective inhibitor that inhibits TGF-β activity by selectively degrading the TGF-β2 receptor at the proteosome level. ITD-1 does not block the closely related Activin A signaling pathway. ITD-1 stimulates embryonic stem cells to differentiate into cardiomyocytes (IC50 0.4-0.8 µM) by degrading the receptor and inhibiting intracellular signaling. ITD-1 has been formulated as a salt to increase stability and improve water solubility (~0.1 mg/mL) for ease of handling. As a salt, ITD-1 is chemically and metabolically stable and is non-cytotoxic. ITD-1 can be used to study a wide range of biological questions in cellular processing and TGF-β signaling.